FALCON

Post-Quantum Cryptography Coalition Launches

Retrieved on: 
Tuesday, September 26, 2023
Software, Technology, Data Management, Security, NIST, PQC, National Cybersecurity Center, IBM, University, National Institute of Science Education and Research, Education, IBM Quantum Experience, FALCON, Microsoft Security Essentials, Computer, Agile management, Intelligence, Microsoft, Research, Government, Public sector, Organization, Algorithm, Knowledge, University of Waterloo, Ecosystem, Quantum, MITRE, Library, Cryptocurrency

To drive progress toward broader understanding and public adoption of post-quantum cryptography (PQC) and the National Institute of Science and Technology’s (NIST) PQC algorithms, a community of technologists, researchers, and expert practitioners launched the PQC Coalition.

Key Points: 
  • To drive progress toward broader understanding and public adoption of post-quantum cryptography (PQC) and the National Institute of Science and Technology’s (NIST) PQC algorithms, a community of technologists, researchers, and expert practitioners launched the PQC Coalition.
  • Founding coalition members include IBM Quantum , Microsoft , MITRE , PQShield , SandboxAQ , and University of Waterloo .
  • “The PQC Coalition will advance the deployment and adoption of these algorithms by bringing together key players across industry, academia, and government.”
    The PQC Coalition will apply its collective technical expertise and influence to facilitate global adoption of PQC in commercial and open-source technologies.
  • The defensive value of post-quantum cryptography to the world depends on all these preparatory steps, plus the actual deployment of PQC in computer systems and products.

AvaWatz Patents FALCON, A New Trust Assessment and Auto-Correction for AI Models and Machine Learning

Retrieved on: 
Tuesday, September 12, 2023
Patent, Natural language processing, Classification, Correction, United States Patent and Trademark Office, FALCON, Deep learning, Computer vision, Explainable artificial intelligence, Machine learning, Artificial intelligence, Avawatz Mountains, Trust (social science), Medical device

The patent application, titled "Systems and Methods for Trust-Aware Error Detection, Correction, and Explainability in Machine Learning and Computer Vision," introduces the AvaWatz approach to make Machine learning and deep learning models more trustworthy and reliable.

Key Points: 
  • The patent application, titled "Systems and Methods for Trust-Aware Error Detection, Correction, and Explainability in Machine Learning and Computer Vision," introduces the AvaWatz approach to make Machine learning and deep learning models more trustworthy and reliable.
  • The more widely applicable machine learning (ML) and artificial intelligence (AI) get, the more we need to ensure trustworthiness and reliability in the AI/ML model predictions.
  • Earlier this year, AvaWatz applied to patent GENIE and introduced the AvaWatz approach to the difficult issue of training data required to train deep learning and machine learning models.
  • We feel that adopting these novel technologies will help many who work with specialized use cases and need to build customized machine learning applications."

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Cognition, Seizure, Therapy, American Epilepsy Society, Health care, FALCON, CTA, Medicine, Dravet syndrome, Oles, Congress, Patient, ADOA, Acadia Pharmaceuticals, OPA1, ASO, Diagnosis, AES, License, Stoke, Collaboration, Safety, Behavior, MHRA, Disease, Pharmaceutical industry, Cryptocurrency

“We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.

Key Points: 
  • “We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.
  • Single and multiple doses of STK-001 from 10mg up to 70mg have been generally well tolerated.
  • During the quarter ended June 30, 2023, Stoke updated its estimate of the total effort it expected to expend to satisfy its performance obligations under the Acadia collaboration.
  • As a result, Stoke recorded a cumulative catch-up adjustment of $(5.3) million which resulted in a reversal of revenue during the quarter ended June 30, 2023.

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
Friday, July 28, 2023
Dai, FALCON, Head, Acquisition, Patient, Fabry disease, SUA, Tissue, Pharma, Gout, Therapy, Heart failure, CSO, GABAA receptor negative allosteric modulator, Research, NAM, VBI, Small RNA, Medicine, Liver, Growth, CIO, Listeria monocytogenes non-coding RNA, Phase, FDA, URAT1, G protein-coupled receptor, SRT, PAR2, DSM-IV codes, Gq alpha subunit, Glaucoma, Ocular hypertension, SAN, Mercury (element), Allosteric regulation, IOP, Flare, Central nervous system, Drug development, Quality of life, Facet joint arthrosis, RNA, Novartis, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Fine chemical, Riparian zone, Domain, Pfizer

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

BTQ's Preon, a Unique Quantum-Secure Signature Technology, Selected by NIST as Candidate for the Post-Quantum Cryptography Standardization Process

Retrieved on: 
Thursday, July 27, 2023
CRYSTALS, Newton, NIST, Preon, Hardness, PQC, Failure, FALCON, Post-quantum cryptography, FSE, Research, HQC, Foxconn, National Institute of Standards and Technology, Algorithm, KEM, AES, Key encapsulation mechanism, Kem, NEO, BTQ, Cryptocurrency

BTQ Technologies Corp.'s post-quantum cryptography scheme, Preon, has been selected by the National Institute of Standards and Technology (NIST) in the first round (additional signatures) for consideration in their Post-Quantum Cryptography (PQC) standardization process.

Key Points: 
  • BTQ Technologies Corp.'s post-quantum cryptography scheme, Preon, has been selected by the National Institute of Standards and Technology (NIST) in the first round (additional signatures) for consideration in their Post-Quantum Cryptography (PQC) standardization process.
  • Preon is a robust and efficient post-quantum signature scheme, showcasing distinctive features including small key size, rapid key generation, minimal assumptions, and flexible functionality.
  • Preon's co-authors include Hon Hai Research Institute, the research arm of global leader Hon Hai Precision Industry Co., Ltd. (Foxconn).
  • With the exception of SPHINCS+, all these selected schemes are based on the computational hardness of problems involving structured lattices.

Workhorse Group Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
ACT, EV, CV, Q3, U.S. Department of Defense Strategy for Operating in Cyberspace, FedEx Ground, Farmer, FALCON, Green, Grand Forks, North Dakota, W56, Draft horse, Growth, Government, United States Department of the Air Force, Research, Airline, Warehouse, Mobile phone, Beauty salon, Air cargo, Pharmaceutical industry, Aerospace

CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.
  • We are making steady progress in expanding our CV dealer network and plan to onboard 8-10 new dealers in 2023.
  • Workhorse will focus on prototype design, test, and build in 2023 and 2024 with production planned to begin 2025.
  • Workhorse is reaffirming its outlook and expects to generate between $75-125 million in revenue in 2023.

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Retrieved on: 
Tuesday, April 25, 2023
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Central nervous system, Life, Serum, DSM-IV codes, FALCON, Health care, Eye, Quality of life, CTA, TANGO, Trial of the century, IVT, Haploinsufficiency, Patient, ADOA, OPA1, ASO, Diagnosis, Stoke, Paratriathlon, Therapy, Safety, MHRA, Disease, Pharmaceutical industry, Vaccine

ADOA is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life.

Key Points: 
  • ADOA is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life.
  • STK-002 is a proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential disease-modifying therapy to address the genetic cause of ADOA.
  • STK-002 is designed to restore OPA1 protein expression by upregulating protein production from the non-mutant (wild-type) copy of the OPA1 gene.
  • By doing this, the company hopes to slow or even stop vision loss in patients with ADOA.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022
LinkedIn, RNA transfection, Therapy, Drug resistance, Professional services, Publication, R, Journalism, Lung cancer, Inflammation, Autoimmunity, Solution, Final good, Erna, News, Lung, Instability, NYSE, Tissue, Invention, Industry, Breast cancer, IP, SMOP, Fibrosis, Listeria monocytogenes non-coding RNA, Ownership, Pharma, Health care, Organization, Intelligence, Research, Cell, Technology, Degenerative disease, FALCON, Clarivate, CNS, Web of Science, Intellectual property, OSCAR, Traction, Disease, Oligonucleotide, Patient, ASO, RNA, Kidney, Report, Sirna, Wisper, Liver, Academy, COVID-19, Lead, List of life sciences, Pharmaceutical industry, Vaccine

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022
LinkedIn, RNA transfection, Therapy, Drug resistance, Professional services, Publication, R, Journalism, Lung cancer, Inflammation, Autoimmunity, Solution, Final good, Erna, News, Lung, Instability, NYSE, Tissue, Invention, Industry, Breast cancer, IP, SMOP, Fibrosis, Listeria monocytogenes non-coding RNA, Ownership, Pharma, Health care, Organization, Intelligence, Research, Cell, Technology, Degenerative disease, FALCON, Clarivate, CNS, Web of Science, Intellectual property, OSCAR, Traction, Disease, Oligonucleotide, Patient, ASO, RNA, Kidney, Report, Sirna, Wisper, Liver, Academy, COVID-19, Lead, List of life sciences, Pharmaceutical industry, Vaccine

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Castle Shield Holdings, LLC Updates the Post-Quantum Cryptography (PQC) Algorithms for Its Data-in-Motion Aeolus VPN Solution

Retrieved on: 
Wednesday, October 12, 2022
Software, Technology, Security, Zero, CRYSTALS, National Institute, MacOS, Physical security information management, Bell–LaPadula model, Senate, NIST, Linux, LLC, UDP, Privacy, SIEM, National Institute of Standards and Technology, Solution, Compliance, Industry, TCP, Legion, FALCON, Sabre, VPN, PQC, Risk, Algorithm, Cryptocurrency, Technology, Microsoft Windows, Dilithium

Castle Shield Holdings, LLC., a leader in Zero Trust and cybersecurity solutions, today announced that its Aeolus VPN solution now supports additional post-quantum cryptography (PQC) algorithms selected by the National Institute of Standards and Technology (NIST).

Key Points: 
  • Castle Shield Holdings, LLC., a leader in Zero Trust and cybersecurity solutions, today announced that its Aeolus VPN solution now supports additional post-quantum cryptography (PQC) algorithms selected by the National Institute of Standards and Technology (NIST).
  • Therefore, we have integrated Kyber (i.e., Kyber1024) and Dilithium (i.e., Dilithium5) algorithms into Aeolus VPN as well.
  • Aeolus VPN offers point-to-point asymmetric PQC and symmetric encryption for UDP and TCP on Windows, Linux and macOS platforms.
  • Our 360 proactive security solutions are what sets Castle Shield apart independent of your IT backbone whether cloud, hybrid or premise based.